On Friday, Viridian Therapeutics Inc (NASDAQ: VRDN) was -6.93% drop from the session before settling in for the closing price of $21.64. A 52-week range for VRDN has been $11.40 – $27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.71%. When this article was written, the company’s average yearly earnings per share was at 24.33%. With a float of $70.14 million, this company’s outstanding shares have now reached $79.21 million.
Let’s determine the extent of company efficiency that accounts for 96 employees. In terms of profitability, gross margin is -2047.68%, operating margin of -93722.52%, and the pretax margin is -85127.15%.
Viridian Therapeutics Inc (VRDN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viridian Therapeutics Inc stocks. The insider ownership of Viridian Therapeutics Inc is 11.45%, while institutional ownership is 98.95%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 24.33% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
You can see what Viridian Therapeutics Inc (VRDN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4949.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.31, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.13 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Looking closely at Viridian Therapeutics Inc (NASDAQ: VRDN), its last 5-days average volume was 1.98 million, which is a jump from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 7.71%. Additionally, its Average True Range was 1.44.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 54.01%, which indicates a significant increase from 6.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.86% in the past 14 days, which was higher than the 73.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.64, while its 200-day Moving Average is $17.16. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $21.39. Second resistance stands at $22.64. The third major resistance level sits at $23.51. If the price goes on to break the first support level at $19.27, it is likely to go to the next support level at $18.40. Should the price break the second support level, the third support level stands at $17.15.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are 79,213K outstanding shares of the company, which has a market capitalization of 1.48 billion. As of now, sales total 310 K while income totals -237,730 K. Its latest quarter income was 70 K while its last quarter net income were -64,990 K.
